Repository logo
 
Publication

Real-World Experience in Treatment of Patients with Non-Small-Cell Lung Cancer with BRAF or cMET Exon 14 Skipping Mutations

dc.contributor.authorJanzic, Urska
dc.contributor.authorShalata, Walid
dc.contributor.authorSzymczak, Katarzyna
dc.contributor.authorDziadziuszko, Rafał
dc.contributor.authorJakopovic, Marko
dc.contributor.authorMountzios, Giannis
dc.contributor.authorPłużański, Adam
dc.contributor.authorA, Araujo
dc.contributor.authorCharpidou, Andriani
dc.contributor.authorAgbarya, Abed
dc.date.accessioned2024-07-23T10:34:05Z
dc.date.available2024-07-23T10:34:05Z
dc.date.issued2023-08
dc.description.abstractBRAF and cMET exon 14 skipping are rare mutations of NSCLC. The treatment sequence in these cases for the first and second line is not clear. An international registry was created for patients with advanced NSCLC harboring BRAF or cMET exon 14 skipping mutations, diagnosed from January 2017 to June 2022. Clinicopathological and molecular data and treatment patterns were recorded. Data on 58 patients, from eight centers across five countries, were included in the final analysis. We found that 40 patients had the cMET exon 14 skipping mutation and 18 had the BRAF V600E mutation. In total, 53 and 28 patients received first- and second-line treatments, respectively, among which 52.8% received targeted therapy (TT) in the first line and 53.5% in the second line. The overall response rate (ORR) and disease control rate (DCR) for first-line treatment with TT vs. other treatment such as immune checkpoint inhibitors ± chemotherapy (IO ± CT) were 55.6% vs. 21.7% (p = 0.0084) and 66.7% vs. 39.1% (p = 0.04), respectively. The type of treatment in first-line TT vs. other affected time to treatment discontinuation (TTD) was 11.6 m vs. 4.6 m (p= 0.006). The overall survival for the whole group was 15.4 m and was not statistically affected by the type of treatment (19.2 m vs. 13.5 m; p = 0.83).pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationJanzic U, Shalata W, Szymczak K, et al. Real-World Experience in Treatment of Patients with Non-Small-Cell Lung Cancer with BRAF or cMET Exon 14 Skipping Mutations. Int J Mol Sci. 2023;24(16):12840. doi:10.3390/ijms241612840pt_PT
dc.identifier.doi10.3390/ijms241612840pt_PT
dc.identifier.issn1422-0067
dc.identifier.urihttp://hdl.handle.net/10400.16/3018
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherMDPIpt_PT
dc.relation.publisherversionhttps://doi.org/10.3390/ijms241612840pt_PT
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt_PT
dc.subjectBRAF V600E mutationpt_PT
dc.subjectcMET exon 14 skipping mutationpt_PT
dc.subjectfirst-line treatmentpt_PT
dc.subjectnon-small-cell lung cancerpt_PT
dc.subjectreal-world datapt_PT
dc.subjecttargeted therapypt_PT
dc.titleReal-World Experience in Treatment of Patients with Non-Small-Cell Lung Cancer with BRAF or cMET Exon 14 Skipping Mutationspt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.conferencePlaceSwitzerlandpt_PT
oaire.citation.issue16pt_PT
oaire.citation.startPage12840pt_PT
oaire.citation.titleInternational Journal of Molecular Sciencespt_PT
oaire.citation.volume24pt_PT
person.familyNameAraújo
person.givenNameAntónio
person.identifier.ciencia-id0715-EC47-869F
person.identifier.orcid0000-0002-7267-3584
person.identifier.ridB-5047-2008
person.identifier.scopus-author-id16229446200
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication782f6844-6bc9-48e9-9967-47d0a20be2c3
relation.isAuthorOfPublication.latestForDiscovery782f6844-6bc9-48e9-9967-47d0a20be2c3

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Janzic-2023-Real-world-experience-in-treatment-.pdf
Size:
299.68 KB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.44 KB
Format:
Item-specific license agreed upon to submission
Description: